



For more information, contact
the Neuro-Oncology
Clinical Trial Team at:
Neuro.Oncology@jwci.org
310-829-8265

Clinical Trial Investigators

Garni Barkhoudarian, MD

Jose Carrillo, MD

Santosh Kesari, MD, PhD

Naveed Wagle, MD

Clinical Trial Team

Tiffany Juarez, PhD
Tiffany.Juarez@jwci.org
310-449-5225

Annie Heng, RN, BSN
Annie.Heng@providence.org
310-582-7457

Hanh Nguyen, CRA
NguyenThuyH@jwci.org
310-582-7434

Ashley Archer, CRA
ArcherA@jwci.org
310-582-7460

Sponsor
PNI/JWCI

CLINICAL TRIAL ANNOUNCEMENT

Pilot Study of Pemetrexed for the Treatment of Chordoma

Official Title:

Pilot Study of Pemetrexed for the Treatment of Chordoma

This is an open-label, single-arm, pilot study of pemetrexed for the treatment of patients with chordoma. The study is designed to assess the safety profile and response rate of high-dose pemetrexed and to collect biological specimens before, during, and after treatment to identify potential biomarkers of response and safety.

Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. Pemetrexed inhibits three enzymes used in the biosynthesis of thymidine and purine nucleotides— thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyl-transferase (GARFT).

Chordomas are rare brain and bone tumors that can occur anywhere along the spine. Surgery and radian therapy are currently used as treatment, as there are no drugs at this time that are approved for treating this cancer type. The current research is being done to determine whether pemetrexed can be used safely and to learn more about how pemetrexed might affect the growth of your chordoma.

Key Inclusion Criteria:

- Diagnosis of chordoma
- Age ≥ 18
- KPS score of ≥ 50

Key Exclusion Criteria:

- Active bacterial infection requiring intravenous antibiotics
- Fungal infection or detectable viral infection